A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial

Yo Murata; Reina Isayama; Shoko Imai; Kensuke Shoji; Mizuho Youndzi; Mami Okada; Masashi Mikami; Shinobu Kobayashi; Kevin Y Urayama; Tohru Kobayashi

doi:10.1016/j.conctc.2022.100892

A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial

Contemp Clin Trials Commun. 2022 Jan 20:26:100892. doi: 10.1016/j.conctc.2022.100892. eCollection 2022 Apr.

Authors

Yo Murata¹, Reina Isayama², Shoko Imai³, Kensuke Shoji⁴, Mizuho Youndzi⁵, Mami Okada⁵, Masashi Mikami⁶, Shinobu Kobayashi⁷, Kevin Y Urayama^{7

8}, Tohru Kobayashi²

Affiliations

¹ Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan.
² Department of Data Science, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
³ Division of Project Management, Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
⁴ Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
⁵ Division of Data Management, Department of Data Science, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
⁶ Division of Biostatistics, Department of Data Science, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
⁷ Department of Social Medicine, National Center for Child Health and Development, Tokyo, Japan.
⁸ Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.

Abstract

Background: Kawasaki disease (KD) is a systemic vasculitis complicated with coronary artery abnormalities (CAAs). Intravenous immunoglobulin reduces the occurrence of CAAs, but significant number of KD patients with CAAs still exists. Thus, new approaches to prevent and attenuate CAAs are warranted. Atorvastatin has been shown to promote endothelial cell homeostasis and suppress vascular inflammation and has received enthusiasm as a potentially new candidate treatment for KD. In the United States, a phase I/IIa dose-escalation study of atorvastatin in KD patients with CAAs demonstrated the safety and pharmacokinetic data of atorvastatin. However, due to the uncertainty in the application of these results to other populations, we aim to examine the tolerability and generate pharmacokinetics data in Japanese KD patients.

Methods: This is a multicenter, single-arm, open-label, phase I/IIa study of atorvastatin in acute KD patients with CAAs in Japan. A minimum of 9 and a maximum of 18 KD patients (2 years-17 years old) will be recruited for a 3 + 3 dose-escalation study of a 6-week course of atorvastatin (0.125-0.5 mg/kg/day). The primary outcome will be safety of atorvastatin. The secondary outcomes will be pharmacokinetics of atorvastatin, activity of atorvastatin and echocardiographic assessment of CAAs. The activity of atorvastatin will include assessment of C-reactive protein or high sensitivity C-reactive protein and white blood cell levels.

Discussion: This study will provide evidence of the safety, tolerability, and pharmacokinetics of atorvastatin in Japanese KD patients and may lead new standard therapy for acute-phase KD associated with CAA complications.

Trial registration: Japan Registry of Clinical Trials (JRCTs031180057). Registered December 19, 2018, https://jrct.niph.go.jp/en-latest-detail/jRCTs031180057.

Keywords: Atorvastatin; Coronary artery aneurysm; Kawasaki disease; Pharmacokinetics; Phase I/IIa study.